Review



antagonist dy268  (TargetMol)


Bioz Verified Symbol TargetMol is a verified supplier
Bioz Manufacturer Symbol TargetMol manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    TargetMol antagonist dy268
    Antagonist Dy268, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/antagonist+dy268/DY268/pmc12871761-49-14-34
    Average 93 stars, based on 1 article reviews
    antagonist dy268 - by Bioz Stars, 2026-09
    93/100 stars

    Images

    Related Articles

    other:

    Article Title: The Microbial Bile Acid Metabolite 3-oxo-LCA Inhibits Colorectal Cancer Progression
    Article Snippet: Natural bile acids such as LCA, 3-oxo-LCA, 6-oxo-LCA, isoalloLCA, FXR synthetic agonist GW4064, and antagonist Dy268, TGR5 agonist INT777, as well as Pan-apoptosis inhibitor Z-VAD-FMK (taregtmol # T7020), were purchased from Cayman Chemicals and TargetMol.



    Similar Products

    fxr antagonist dy268  (MedChemExpress)
    94
    MedChemExpress fxr antagonist dy268
    Fxr Antagonist Dy268, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/antagonist+dy268/DY268/pm41819510-68-0-8
    Average 94 stars, based on 1 article reviews
    fxr antagonist dy268 - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    antagonist dy268  (TargetMol)
    93
    TargetMol antagonist dy268
    Antagonist Dy268, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/antagonist+dy268/DY268/pmc12871761-49-14-34
    Average 93 stars, based on 1 article reviews
    antagonist dy268 - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    dy268 (fxr antagonist)  (Axon Medchem LLC)
    90
    Axon Medchem LLC dy268 (fxr antagonist)
    Effect of seladelpar on the FXR pathway in primary mouse hepatocytes. Primary mouse hepatocytes were treated with either seladelpar (10 μM) or the FXR agonist GW4064 (10 μM) in combination with either DMSO or the FXR antagonist <t>DY268</t> (10 μM) for 48 h, and gene expression analysis was performed. Data are presented as mean ± S.E.M. of at least three independent replicates. ∗ p < 0.05 and ∗∗ p < 0.01 denote the significant difference between control and seladelpar or GW4064 in each condition. FXR, Farnesoid X receptor.
    Dy268 (Fxr Antagonist), supplied by Axon Medchem LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/antagonist+dy268/dy+268+2561/pmc09214809-132-0-5
    Average 90 stars, based on 1 article reviews
    dy268 (fxr antagonist) - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Effect of seladelpar on the FXR pathway in primary mouse hepatocytes. Primary mouse hepatocytes were treated with either seladelpar (10 μM) or the FXR agonist GW4064 (10 μM) in combination with either DMSO or the FXR antagonist DY268 (10 μM) for 48 h, and gene expression analysis was performed. Data are presented as mean ± S.E.M. of at least three independent replicates. ∗ p < 0.05 and ∗∗ p < 0.01 denote the significant difference between control and seladelpar or GW4064 in each condition. FXR, Farnesoid X receptor.

    Journal: The Journal of Biological Chemistry

    Article Title: Selective PPARδ agonist seladelpar suppresses bile acid synthesis by reducing hepatocyte CYP7A1 via the fibroblast growth factor 21 signaling pathway

    doi: 10.1016/j.jbc.2022.102056

    Figure Lengend Snippet: Effect of seladelpar on the FXR pathway in primary mouse hepatocytes. Primary mouse hepatocytes were treated with either seladelpar (10 μM) or the FXR agonist GW4064 (10 μM) in combination with either DMSO or the FXR antagonist DY268 (10 μM) for 48 h, and gene expression analysis was performed. Data are presented as mean ± S.E.M. of at least three independent replicates. ∗ p < 0.05 and ∗∗ p < 0.01 denote the significant difference between control and seladelpar or GW4064 in each condition. FXR, Farnesoid X receptor.

    Article Snippet: DY268 (FXR antagonist) was from Axon Medchem.

    Techniques: Gene Expression, Control